MannKind (NSDQ:MNKD) said today that it inked a deal with a group of unnamed investors for a registered direct offering of 10,166,600 shares of the company’s common stock for $6.00 apiece. The $61 million offering is slated to close later this week. Get the full story at our sister site, Drug Delivery Business News.
Shares in MannKind Corp. (NSDQ:MNKD) fell slightly this morning after the biopharmaceutical company missed earnings expectations but beat sales estimates on Wall Street with its second quarter results. The Valencia, Calif.-based company posted a net loss of -$35.4 million on sales of $2.2 million for the 3 months ended June 30, for bottom-line loss of -18% on sales growth of […]
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the group launched its A-One trial evaluating MannKind’s inhaled insulin, Afrezza, for use with One Drop’s digital diabetes management platform. The companies reported that they are enrolling people with Type II diabetes and randomizing them in two treatment arms. One group of patients will use Afrezza with One Drop […]
Lumicell said last week it tapped former Accuray (NSDQ:ARAY) chief operating officer Kelly Londy as its new chief exec, with founder W. Lee moving to take the role of prez & chief scientific officer. Prior to holding the COO position at Accuray, Londy has held leadership positions at GE Healthcare (NYSE:GE) and Royal Philips (NYSE:PHG), Lumicell said. “We are […]
MannKind Corp. (NSDQ:MNKD) said today that inked a supply and distribution deal with Biomm for the commercialization of its inhaled insulin, Afrezza, in Brazil. According to the agreement, Biomm will prepare and file the necessary applications for regulatory approval. MannKind will be responsible for manufacturing and supplying Afrezza and Biomm is slated to promote and […]
Shares in MannKind Corp. (NSDQ:MNKD) fell this week after the biopharmaceutical company missed expectations on Wall Street with its 1st quarter results. The Valencia, Calif.-based company pared its losses to -$16.3 million on sales of $3 million for the 3 months ended March 31, for bottom-line growth of 53% compared with the same period last year. […]
MannKind Corp. (NSDQ:MNKD) and One Drop said today that the companies agreed to ink a collaborative deal to add MannKind’s Afrezza inhaled insulin to One Drop’s digital diabetes management platform. The group plans to evaluate access and cost saving initiatives, customized patient coaching and innovative packaging for a reusable Afrezza inhaler integrated with Bluetooth tech. […]
Mannkind chief commercial officer Michael Castagna is trying to resuscitate the inhaled insulin maker after its co-marketing agreement with Sanofi (NYSE:SNY) was cancelled at the beginning of the year due to disappointing sales. He’s fielding a team of about 70 people to sell the company’s Afrezza insulin inhaler, with about ⅓ coming from the medical […]
MannKind Corporation said today it withdrew an offer that would have made ex-Insulet (NSDQ:PODD) CEO Duane DeSisto its new CEO only 19 days after officially posting its offer to DeSisto. The offer was withdrawn as objections were raised by DeSisto’s former employer Insulet, who said the new position would violate its non-competition agreement, which will be […]
MannKind Corporation said last week it picked up ex-Insulet (NSDQ:PODD) CEO Duane DeSisto as its new prez and CEO, effective January 5, 2016. DeSisto will replace interim CEO Alfred Mann, who has held the spot since November. DeSisto will also join the company’s board of directors, according to a press release from the Valencia, Calif.-based company. […]
Second Sight Medical is looking to bridge the gap to its forthcoming initial public offering with a $3 million loan from iconic chairman Al Mann.